March 16th 2023
Kidney Cancer Association president Gretchen Vaughan discusses improvements being rolled out by the organization and the importance of multidisciplinary care.
PET/CT Imaging Agent Demonstrates Real-World Specificity/Sensitivity in RCCFebruary 20th 2023
89Zr-DFO-girentuximab improves sensitivity and specificity in identifying clear cell kidney cancer compared with any metric to date, according to an expert from the University of California, Los Angeles.
Frontline Cabozantinib Yields Early Responses After CPI Combos in RCCFebruary 19th 2023
Patients with locally advanced or metastatic renal cell carcinoma with a clear-cell component who receive first-line cabozatinib after checkpoint inhibitor combination therapy appear to have early responses.
Cabozantinib Combo Shows Boost in Efficacy in Advanced Kidney Cancer SubgroupsFebruary 18th 2023
When combined with nivolumab and ipilimumab, cabozantinib appears to improve outcomes over placebo for patients with advanced, intermediate-risk renal cell cancer, and showed some efficacy among the poor-risk population.
Long-Term Stereotactic Ablative Body Radiotherapy Demonstrates Lasting Efficacy/Safety in Kidney Cancer SubtypeJanuary 12th 2023
Data from a meta-analysis suggest that single-fraction stereotactic ablative body radiotherapy could result in a lower incidence of local failure than multifractionated radiation in patients with renal cell carcinoma.
First-Line Therapy for Advanced RCC: Optimizing Adverse Event ManagementJanuary 2nd 2023
A brief review of common adverse events inherent in the first-line management of advanced renal cell carcinoma and practical advice on how to mitigate treatment toxicity.
Overview of First-Line Treatment Options for Advanced RCCJanuary 2nd 2023
Opening their discussion on the advanced renal cell carcinoma treatment landscape, experts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, identify cornerstone first-line regimens.
‘Absolutely Important’ to Develop Better Ways to Predict Kidney Cancer Recurrence, Says ExpertDecember 28th 2022
Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.
Why European Experts Cautiously Recommend Pembrolizumab to Treat High-Risk Kidney Cancer Following SurgeryDecember 27th 2022
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
‘Number of Unanswered Questions’ Remain About Role of Stereotactic Radiation in Metastatic Kidney CancerDecember 26th 2022
An expert from the University of Texas Southwestern Medical Center questions how providers are currently utilizing stereotactic radiation in the treatment of metastatic kidney cancer.
Urologists Should Make Patients With Metastatic Kidney Cancer Aware that not All Trials Have Positive Results, Says ExpertDecember 25th 2022
Patients with kidney cancer should be made aware of trials that have not read out positively in the adjuvant setting, according to an expert from the Royal Free London NHS Foundation Trust.
‘Interesting’ Research Continues to Assess the Role of Radiation in Management of Metastatic Kidney CancerDecember 21st 2022
Ongoing clinical trials are exploring the cytoreductive properties and immunogenic potential of stereotactic radiation in the treatment of patients with metastatic kidney cancer, according to an expert from the University of Texas Southwestern Medical Center.
Interpreting Adjuvant Therapy Trial Results in Advanced RCCDecember 19th 2022
Before closing out their discussion on the evolving treatment landscape of advanced renal cell carcinoma, Matthew Campbell, MD, MS, and Brian Rini, MD, highlight clinical trials in the adjuvant setting.
Advanced Renal Cell Carcinoma: Nuancing Triplet Therapy Trial ResultsDecember 19th 2022
Shared insight on the results from triplet therapy–centered clinical trials in advanced renal cell carcinoma and how these might inform treatment strategies as the paradigm continues to evolve.
First-Line Clinical Trial Data in Advanced Renal Cell CarcinomaDecember 12th 2022
A broad look at the data from several recent first-line clinical trials in the setting of advanced renal cell carcinoma and considerations for how they may impact real-world practice.
Renal Cell Carcinoma: Overlapping Toxicity in TKI/IO Combination TherapyDecember 5th 2022
Closing out their discussion on adverse event management in advanced renal cell carcinoma, Matthew Campbell, MD, MS, and Brian Rini, MD, consider overlapping toxicity in TKI/IO regimens.
SBRT Controls Metastatic Kidney Cancer ‘For As Much as 2 Years’, Says ExpertDecember 4th 2022
An expert from the University of Texas Southwestern Medical Center in Dallas describes the efficacy of stereotactic radiation in the treatment of patients with metastatic kidney cancer.
How SBRT Has Evolved Over the Decades to Manage Kidney CancerDecember 3rd 2022
An expert from the University of Texas Southwestern Medical Center in Dallas gives an overview of the multimodal use of stereotactic radiation for the treatment of patients with metastatic kidney cancer.